FDA to allow midstream changes to device trials as part of effort to speed up approvals
The FDA continued its focus on improving the clinical trial paradigm with this week’s issuance of a draft guidance on adaptive designs for medical device clinical studies. Similar to a prior guidance on the incorporation of patient preference data in clinical trials, the latest guidance should help companies perform trials faster, and signals greater flexibility on the behalf of the FDA. The Agency seeks to bring more trials stateside and approve medical technology at a quicker pace.